Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jerrold Turner
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Thelium Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research proposes to define the molecular mechanisms of basal and TNF-induced MLCK1 trafficking and to characterize the therapeutic potential of newly-discovered trafficking inhibitors in experimental IBD, and to address challenges to translation of earlier observations to human patients. It will link specific mechanisms of barrier loss to disease and identify novel therapeutic approaches. Thelium Therapeutics is developing therapeutics to restore epithelial and endothelial tissue barriers.
THE MYOSIN LIGHT CHAIN KINASE-PHOSPHATASE AXIS IN GI HOMEOSTASIS AND DISEASE
The proposed research is relevant to public health because discovery of the mechanisms that regulate tissue barriers that separate sterile internal compartments from those colonized by microbiota, e.g. the intestinal lumen, and agents that modify this these processes will provide a foundation for development therapeutic interventions to maintain or restore barrier function in disease. This work will therefore directly support the overall NIH mission of developing fundamental knowledge that will help reduce the burden of human disease and promote the NIDDK goal of improving digestive health.
Filed on March 21, 2019.
Tell us what you know about Jerrold Turner's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jerrold Turner filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jerrold Turner | Brigham and Women's Hospital | Conflict of Interest | Thelium Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.